222 related articles for article (PubMed ID: 35632574)
1. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
Lapa D; Grousova DM; Matusali G; Meschi S; Colavita F; Bettini A; Gramigna G; Francalancia M; Garbuglia AR; Girardi E; Puro V; Antinori A; Kovyrshina AV; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Gushchin VA; Logunov DY; Naroditsky BS; Vaia F; Gintsburg AL
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632574
[TBL] [Abstract][Full Text] [Related]
2. Functional Characteristics of Serum Anti-SARS-CoV-2 Antibodies against Delta and Omicron Variants after Vaccination with Sputnik V.
Radion EI; Mukhin VE; Kholodova AV; Vladimirov IS; Alsaeva DY; Zhdanova AS; Ulasova NY; Bulanova NV; Makarov VV; Keskinov AA; Yudin SM
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376648
[TBL] [Abstract][Full Text] [Related]
3. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
5. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
6. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
[TBL] [Abstract][Full Text] [Related]
7. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada.
Rabezanahary H; Gilbert C; Santerre K; Scarrone M; Gilbert M; Thériault M; Brousseau N; Masson JF; Pelletier JN; Boudreau D; Trottier S; Baz M
Heliyon; 2024 May; 10(10):e31026. PubMed ID: 38826717
[TBL] [Abstract][Full Text] [Related]
8. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
9. Plasma neutralization properties of the SARS-CoV-2 Omicron variant.
Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
medRxiv; 2021 Dec; ():. PubMed ID: 34931199
[TBL] [Abstract][Full Text] [Related]
10. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.
Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines.
Peiris M; Cheng S; Mok CKP; Leung Y; Ng S; Chan K; Ko F; Yiu K; Lam B; Lau E; Chan K; Luk L; Li J; Tsang L; Poon L; Chen C; Hui D
Res Sq; 2022 Jan; ():. PubMed ID: 35018372
[TBL] [Abstract][Full Text] [Related]
13. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
[TBL] [Abstract][Full Text] [Related]
14. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
15. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
16. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
[TBL] [Abstract][Full Text] [Related]
17. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
Gruell H; Vanshylla K; Tober-Lau P; Hillus D; Schommers P; Lehmann C; Kurth F; Sander LE; Klein F
Nat Med; 2022 Mar; 28(3):477-480. PubMed ID: 35046572
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
[TBL] [Abstract][Full Text] [Related]
19. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant.
Zhou Z; Du P; Li N; Xiong X; Tang S; Dai Q; Wang T; Yu M; Man M; Lam K; Baptista-Hon DT; Tai WH; Monteiro O; Ng WS; Lee UM; Liu Z; Zhang K; Li G
MedComm (2020); 2022 Jun; 3(2):e143. PubMed ID: 35592756
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
Blanco S; Salomé Konigheim B; Diaz A; Spinsanti L; Javier Aguilar J; Elisa Rivarola M; Beranek M; Collino C; MinSalCba Working Group ; Fcm-Unc Working Group ; Diaz M; Gabriela Barbás M; Mangeaud A; Verónica Gallego S
Vaccine; 2022 Jan; 40(5):811-818. PubMed ID: 34953609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
